The issuance of senior unsecured notes by Bristol Myers Squibb will increase the company's debt, which could affect its financial structure. However, the impact on the stock price is uncertain as it depends on how the market perceives this move. It could be seen as a positive sign of growth and expansion, or it could raise concerns about increased financial risk.